October 2019
Mindful Awareness in Body-Oriented Therapy (MABT) improved emotion regulation, reduced craving, and promoted abstinence in women with a history of trauma and emotional problems receiving outpatient treatment for substance use disorder.
October 2019
This study demonstrated that functional connectivity among a large number of brain regions predicts patients’ chances of achieving abstinence in treatment for cocaine use disorder.
August 2019
This study showed that rats will forgo heroin and methamphetamine in favor of spending time with another rat. It also highlights the importance of incorporating voluntary choice between drugs and social rewards in drug addiction research.
April 2019
Prisoners who received methadone maintenance treatment (MMT) during incarceration were more likely than prisoners who did not receive MMT to engage in the treatment after being released.
March 2019
Interim treatment with buprenorphine significantly improved the psychiatric symptoms of people awaiting comprehensive treatment for opioid use disorder (OUD). Buprenorphine treatment, even without concurrent psychosocial counseling, may help patients with no, or delayed, access to comprehensive OUD treatment.
February 2019
An experimental compound with a dual action at two opioid receptors may provide powerful pain relief without many of opioids' harmful side effects.
En Español
October 2018
Mindfulness-Oriented Recovery Enhancement (MORE) reduces opioid misuse among chronic pain patients. MORE shifts patients' attention away from drug cues and toward cues for natural rewards.
October 2018
Smokers who switch to cigarettes with very low nicotine content may experience mild and transient increases in some withdrawal symptoms. Cigarettes with reduced nicotine will be easier to quit than the cigarettes marketed at present.
June 2018
A clinical trial found that patients who self-administered cognitive behavioral therapy (CBT) using computerized training modules reduced their drug use as much as patients who received clinician-delivered CBT, and they maintained this advantage through a 6-month follow-up.
June 2018
In rats, the combination treatment of oxycodone/nalfurafine had lower levels of abuse liability and produced less respiratory depression than oxycodone alone.
